Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 171.7%

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 57,600 shares, a growth of 171.7% from the February 29th total of 21,200 shares. Based on an average trading volume of 222,200 shares, the short-interest ratio is currently 0.3 days. Approximately 0.4% of the company’s stock are sold short.

Xilio Therapeutics Trading Up 69.0 %

Shares of Xilio Therapeutics stock opened at $1.08 on Friday. The company has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $1.16. Xilio Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.67. The stock has a market cap of $29.75 million, a price-to-earnings ratio of -0.36 and a beta of -0.32.

Hedge Funds Weigh In On Xilio Therapeutics

A number of large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. purchased a new position in shares of Xilio Therapeutics in the 2nd quarter valued at about $31,000. Dimensional Fund Advisors LP purchased a new position in shares of Xilio Therapeutics in the 1st quarter valued at about $57,000. Bank of New York Mellon Corp increased its holdings in shares of Xilio Therapeutics by 47.7% in the 1st quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company’s stock valued at $149,000 after purchasing an additional 6,791 shares in the last quarter. Morgan Stanley increased its holdings in shares of Xilio Therapeutics by 274.4% in the 4th quarter. Morgan Stanley now owns 25,611 shares of the company’s stock valued at $69,000 after purchasing an additional 18,771 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Xilio Therapeutics by 30.2% in the 4th quarter. Renaissance Technologies LLC now owns 37,100 shares of the company’s stock valued at $100,000 after purchasing an additional 8,600 shares in the last quarter. Hedge funds and other institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.